Asia Pacific Pulmonary Arterial Hypertension Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Asia Pacific Pulmonary Arterial Hypertension Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Asia Pacific Pulmonary Arterial Hypertension Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Rising cases of pulmonary arterial hypertension (PAH)
5.1.2 New targeted therapies for PAH treatment

5.2 Market Opportunities

5.2.1 Growth of generics and biosimilars in PAH treatments
5.2.2 Research into combination therapies and personalized medicine

5.3 Future Trends

5.3.1 Shift toward oral therapies for PAH management
5.3.2 Development of new drug classes for PAH treatment

5.4 Impact of Drivers and Restraints

6. Asia Pacific Pulmonary Arterial Hypertension Market Regional Analysis

6.1 Asia Pacific Pulmonary Arterial Hypertension Market Overview

6.2 Asia Pacific Pulmonary Arterial Hypertension Market Revenue 2020-2028 (US$ Million)

6.3 Asia Pacific Pulmonary Arterial Hypertension Market Forecast Analysis

7. Asia Pacific Pulmonary Arterial Hypertension Market Analysis – by Drugs

7.1 Endothelin Receptor Antagonists

7.1.1 Overview
7.1.2 Endothelin Receptor Antagonists: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Prostacyclin and Prostacyclin Analogs

7.2.1 Overview
7.2.2 Prostacyclin and Prostacyclin Analogs: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2031 (US$ Million)

7.3 sGC Stimulators

7.3.1 Overview
7.3.2 sGC Stimulators: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2031 (US$ Million)

7.4 pde-5 Dipsticks

7.4.1 Overview
7.4.2 pde-5 Dipsticks: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Pulmonary Arterial Hypertension Market Analysis – by Type

8.1 Branded and Generics

8.1.1 Overview
8.1.2 Branded and Generics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Pulmonary Arterial Hypertension Market Analysis – by Route of Administration

9.1 Oral

9.1.1 Overview
9.1.2 Branded and Generics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.2 Intravenous/Subcutaneous

9.2.1 Overview
9.2.2 Branded and Generics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.3 Inhalational

9.3.1 Overview
9.3.2 Branded and Generics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Pulmonary Arterial Hypertension Market – Asia-Pacific Analysis

10.1 Asia-Pacific

10.1.1 Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Key Country, 2023 and 2028 (%)
10.1.1.1 Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast Analysis – by Country
10.1.1.1 China: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 China: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Drugs
10.1.1.1.2 China: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Type
10.1.1.1.3 China: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration

10.1.1.2 India: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.2.1 India: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Drugs
10.1.1.2.2 India: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Type
10.1.1.2.3 India: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration

10.1.1.3 Japan: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.3.1 Japan: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Drugs
10.1.1.3.2 Japan: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Type
10.1.1.3.3 Japan: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration

10.1.1.4 Australia: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.4.1 Australia: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Drugs
10.1.1.4.2 Australia: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Type
10.1.1.4.3 Australia: Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration

10.1.1.5 Rest of Asia-Pacific : Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Drugs
10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Type
10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Pulmonary Arterial Hypertension Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Asia Pacific Pulmonary Arterial Hypertension Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Bayer AG

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Gilead Sciences Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 GSK Plc

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Johnson & Johnson

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Lupin Ltd

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Novartis AG

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Pfizer Inc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Teva Pharmaceutical Industries Ltd

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights